Kidron Miriam 4

What Happened Miriam Kidron, Chief Scientific Officer and a director of Oramed Pharmaceuticals (ORMP), disposed of 435,084 shares on 2026-03-30 to satisfy tax withholding obligations tied to vested restricted stock units. The shares were valued at $3.31 each (the prior trading day's close), for a total value of approximately $1,440,128. This was a tax-withholding-related disposition (routine), not an open-market sale for cash.

Key Details

• Transaction date: 2026-03-30; filing date: 2026-03-31 (timely).
• Shares surrendered/disposed: 435,084 at $3.31 per share; total value ≈ $1,440,128.
• Transaction code: F (shares used to satisfy tax withholding upon RSU vesting).
• Footnote: Shares used to satisfy withholding were valued at the closing price on the date immediately prior to vesting ($3.31) per filing.
• Shares owned after the transaction: not specified in this Form 4.

Context This was a cashless-type disposition to cover tax liabilities from RSU vesting (common practice) and does not necessarily indicate the insider's view of the company's stock. Tax-withholding dispositions are routine and are treated differently from deliberate open-market sales or purchases.